|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.50 USD | -1.05% |
|
+1.16% | +28.91% |
| 07-07 | RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating | MT |
| 07-02 | Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | Bio Therapeutic Drugs | -1.05% | +1.16% | +28.91% | +25.95% | +213.71% | 14.2B |  | | |
- Stock Market
- Stocks
- EXEL Stock
- Charts Exelixis, Inc.
- Comparison Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
